Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

EnergieShake® Acceptability and Tolerance Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02788032
Recruitment Status : Unknown
Verified May 2016 by Anaiah Healthcare Pvt Ltd.
Recruitment status was:  Not yet recruiting
First Posted : June 2, 2016
Last Update Posted : June 2, 2016
Sponsor:
Information provided by (Responsible Party):
Anaiah Healthcare Pvt Ltd

Tracking Information
First Submitted Date  ICMJE May 24, 2016
First Posted Date  ICMJE June 2, 2016
Last Update Posted Date June 2, 2016
Study Start Date  ICMJE July 2016
Estimated Primary Completion Date July 2016   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: June 1, 2016)
Tolerance: how well the participant tolerates the Oral Nutritional Supplement, including changes to gastrointestinal symptoms. [ Time Frame: 10 days ]
The primary objective of the study is to assess gastrointestinal (GI) tolerance (bowel frequency and consistency using the Bristol Stool Chart, nausea, vomiting, abdominal discomfort, wind, burping, flatulence) to test Oral Nutrition Supplement (EnergieShake®, a powdered nutritional supplement, classified as a Food for Special Medical Purposes for the dietary management of disease-related malnutrition) in patients requiring ONS.
Original Primary Outcome Measures  ICMJE Same as current
Change History No Changes Posted
Current Secondary Outcome Measures  ICMJE
 (submitted: June 1, 2016)
How acceptable the Oral Nutritional Supplement is to the participant, (taste, texture, aroma, consistency, etc.) Compliance with Oral Nutritional Supplement. [ Time Frame: 10 days ]
Assessment on Taste Questionnaire used asks patients to rate appearance, taste/flavour, texture/consistency, Aroma/smell, Taste/sweetness, and overall acceptability using Hedonic scale: 9 (like extremely) to 1 (dislike extremely).
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE EnergieShake® Acceptability and Tolerance Study
Official Title  ICMJE Open Label Study of Acceptability, Tolerance, and Compliance Using EnergieShake® Dietary Powdered Supplement
Brief Summary

This open-label, prospective, controlled intervention study involves evaluating tolerance and acceptability of an Oral Nutrition Supplement (ONS; EnergieShake®) in 16 adult patients who are already taking an ONS. Following a 2-day baseline data collection on their current ONS, patients switch to the test ONS, which is taken for a further 8 consecutive days. Patients revert to their current ONS at the end of the study. Patients act as their own controls and thus all patients are allocated the same intervention.

Daily records of GI tolerance and compliance with the prescribed amount of ONS will be kept for participants throughout the study period. Participants' height and weight will be collected at baseline (weight at end will also be collected), all medications will be documented, and relevant medical and dietary histories will be recorded. A questionnaire at the end of the intervention period will be administered collecting participants' views on the acceptability (taste and palatability) of the test ONS. Taste and palatability will be assessed via a questionnaire that uses a Hedonic scale to quantify preference.

Detailed Description

INTRODUCTION, BACKGROUND INFORMATION AND SCIENTIFIC RATIONALE

Background Information

This open-label study involves evaluating tolerance and acceptability of the test ONS in 16 adult participants who are already taking an ONS. Following a 2-day baseline data collection on their current ONS, patients switch to the test ONS, which is taken for a further 8 consecutive days. Patients revert to their current ONS at the end of the study. Patients act as their own controls and thus all patients are allocated the same intervention.

Rationale

Patient tolerance and acceptability is fundamental to the successful use of an ONS. Acceptability and tolerance studies for ONS are required by the Advisory Committee on Borderline Substances (ACBS) as part of a submission for a new product to be made available at NHS expense in the community.

Potential Risks and Benefits

Potential Risks

There are no anticipated risks to participants. Participants will already be taking other ONS as this is one of the inclusion criteria. Minimal inconvenience to participants is anticipated as they will be asked to complete a questionnaire on the product's acceptability. Daily records on the GI tolerance of the product will be recorded by participants or nursing staff. Most of the study documentation will be completed by the study staff.

Potential Benefits

Participants may gain weight or maintain their weight during the intervention. In the future, if this product becomes available on prescription, a wider variety of ONS available to patients may lessen taste fatigue associated with taking the same supplements over an extended period.

STUDY OBJECTIVES

Primary study objective

The primary objective of the study is to assess gastrointestinal (GI) tolerance (bowel frequency and consistency using the Bristol Stool Chart, nausea, vomiting, abdominal discomfort, wind, burping, flatulence) to a Test Oral Nutrition Supplement (EnergieShake®, a powdered nutritional supplement, classified as a Food for Special Medical Purposes for the dietary management of disease-related malnutrition) in patients requiring ONS.

Secondary study objective

The secondary objective is to assess acceptability of the product.

STUDY DESIGN

This study is an open-label, prospective, controlled intervention in which participants act as their own controls. Guidance from ACBS requires that acceptability and tolerance studies must normally be carried out on at least 15 patients in the intended target group for a period of 1 week. The design of this study has been based on the guidance provided by ACBS.

STUDY ENROLLMENT AND WITHDRAWAL

Strategies for Recruitment and Retention

Potentially suitable participants will be identified by staff at the site. Participants who may be suitable are those who are currently taking ONS and whose requirement for ONS is expected to continue for at least a further 2 weeks. They will be approached by staff at the site and provided with a Participant Information Sheet and letter of invitation from the sponsor (Anaiah Healthcare Ltd). To ensure this process is free from undue influence, residents will not be coerced or offered inducements to participate.

Subject Withdrawal

Reasons for Withdrawal

Participants will have the choice of whether or not to withdraw from the study at any stage for any reason. Should the participant experience any adverse event or discomfort due to consuming the product, the participant will be advised to stop using the product.

Handling of Subject Withdrawals or Subject Discontinuation of Study Intervention

If the participant discontinues the study before the intervention is complete, their permission will be sought to use the data collected on the use of the product. A replacement of a participant who withdraws will be recruited to meet the requirement target that at least 15 patients provide data on the test ONS.

Study Type  ICMJE Interventional
Study Phase  ICMJE Not Applicable
Study Design  ICMJE Intervention Model: Single Group Assignment
Masking: None (Open Label)
Condition  ICMJE Malnutrition
Intervention  ICMJE Other: EnergieShake oral supplement
The participants will be given EnergieShake® powdered nutritional supplement twice daily during the study period in place of their usual ONS. Participants will take their usual ONS for 2 days followed by an 8 day intervention on EnergieShake®
Study Arms  ICMJE EnergieShake Intervention
Single arm of intervention of Oral Nutritional Supplement in the open label study to be given to participants for 8 days Two 57g sachets of EnergieShake daily to be given to participants during the 8 day intervention period.
Intervention: Other: EnergieShake oral supplement
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Unknown status
Estimated Enrollment  ICMJE
 (submitted: June 1, 2016)
18
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE July 2016
Estimated Primary Completion Date July 2016   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Adult (18 years or older)
  • Participants with or at risk of malnutrition who are already taking ONS on a daily basis
  • Participants expected to continue to require ONS for at least a further 2 weeks
  • Participants able to give their informed consent to participate

Exclusion Criteria:

  • Requirement of tube or parenteral nutrition.
  • Participants receiving palliative care.
  • Participants with chronic renal disease or liver failure.
  • Participants requiring a milk/lactose free diet
  • Participants with significant on-going gastrointestinal symptoms.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years to 90 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United Kingdom
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT02788032
Other Study ID Numbers  ICMJE AHCES 005
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE
Plan to Share IPD: No
Responsible Party Anaiah Healthcare Pvt Ltd
Study Sponsor  ICMJE Anaiah Healthcare Pvt Ltd
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Principal Investigator: Ryan Rodrigues, Masters Anaiah Healthcare Ltd
PRS Account Anaiah Healthcare Pvt Ltd
Verification Date May 2016

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP